3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 4
2
Phase 2
2
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Stomatitis
1
Stomach Neoplasms
1
Solid Tumor Refractory to Standard Therapy
1
Sarcoma
1
Precancerous Conditions
1
Pancreatic Neoplasms
1
Ototoxicity
1
Mycosis Fungoides
1
Mucositis
1
Mouth Neoplasms
1
Meningioma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell, Marginal Zone
1
Leiomyoma
1
Hodgkin Disease
1
Hearing Loss
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Fatigue
1
Dermatomyositis
1
Breast Neoplasms
1
Brain Neoplasms
1
Anemia
1
Interventions
Temozolomide
38
Radiotherapy
21
Radiosurgery
21
Irinotecan
11
Cyclophosphamide
11
Radiation
10
Magnetic Resonance Spectroscopy
10
Etoposide
10
Surgical Procedures, Operative
9
Erlotinib Hydrochloride
9
Carmustine
9
Filgrastim
8
Carboplatin
8
pembrolizumab
7
Bevacizumab
7
Vincristine
6
Sorafenib
6
O(6)-benzylguanine
6
Nivolumab
6
Flucytosine
6
Aminolevulinic Acid
6
temsirolimus
5
sargramostim
5
Vorinostat
5
Trastuzumab
5
Topotecan
5
Imatinib Mesylate
5
Granulocyte Colony-Stimulating Factor
5
Everolimus
5
cediranib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Brain Neoplasms
×
Sodium Chloride
×
Clear all
NCT03177252
2020-10-22
Scalp block
Washington University School of Medicine
Phase 1
Withdrawn